The current and projected economic burden of Parkinson's disease in the United States - PubMed (original) (raw)
doi: 10.1002/mds.25292. Epub 2013 Feb 21.
Affiliations
- PMID: 23436720
- DOI: 10.1002/mds.25292
The current and projected economic burden of Parkinson's disease in the United States
Stacey L Kowal et al. Mov Disord. 2013 Mar.
Abstract
Parkinson's disease (PD), following Alzheimer's disease, is the second-most common neurodegenerative disorder in the United States. A lack of treatment options for changing the trajectory of disease progression, in combination with an increasing elderly population, portends a rising economic burden on patients and payers. This study combined information from nationally representative surveys to create a burden of PD model. The model estimates disease prevalence, excess healthcare use and medical costs, and nonmedical costs for each demographic group defined by age and sex. Estimated prevalence rates and costs were applied to the U.S. Census Bureau's 2010 to 2050 population data to estimate current and projected burden based on changing demographics. We estimate that approximately 630,000 people in the United States had diagnosed PD in 2010, with diagnosed prevalence likely to double by 2040. The national economic burden of PD exceeds 14.4billionin2010(approximately14.4 billion in 2010 (approximately 14.4billionin2010(approximately22,800 per patient). The population with PD incurred medical expenses of approximately 14billionin2010,14 billion in 2010, 14billionin2010,8.1 billion higher ($12,800 per capita) than expected for a similar population without PD. Indirect costs (e.g., reduced employment) are conservatively estimated at 6.3billion(orcloseto6.3 billion (or close to 6.3billion(orcloseto10,000 per person with PD). The burden of chronic conditions such as PD is projected to grow substantially over the next few decades as the size of the elderly population grows. Such projections give impetus to the need for innovative new treatments to prevent, delay onset, or alleviate symptoms of PD and other similar diseases.
Copyright © 2012 Movement Disorders Society.
Similar articles
- Burden of illness in Parkinson's disease.
Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Huse DM, et al. Mov Disord. 2005 Nov;20(11):1449-54. doi: 10.1002/mds.20609. Mov Disord. 2005. PMID: 16007641 - Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review. - Drug and treatment costs in Parkinson's disease patients in Sweden.
Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Lökk J, et al. Acta Neurol Scand. 2012 Feb;125(2):142-7. doi: 10.1111/j.1600-0404.2011.01517.x. Epub 2011 Apr 6. Acta Neurol Scand. 2012. PMID: 21470194 - Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.
Noyes K, Liu H, Li Y, Holloway R, Dick AW. Noyes K, et al. Mov Disord. 2006 Mar;21(3):362-72. doi: 10.1002/mds.20727. Mov Disord. 2006. PMID: 16211621 - Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
Chen JJ. Chen JJ. Am J Manag Care. 2010 Mar;16 Suppl Implications:S87-93. Am J Manag Care. 2010. PMID: 20297871 Review.
Cited by
- Annual Cost of Care of Parkinson's Disease and Its Determinants in North India - A Cost of Illness Study with Patient Perspective.
Ola V, Puri I, Goswami D, Vibha D, Shukla G, Goyal V, Srivastava A, Behari M. Ola V, et al. Ann Indian Acad Neurol. 2022 Jul-Aug;25(4):660-663. doi: 10.4103/aian.aian_779_21. Epub 2022 May 3. Ann Indian Acad Neurol. 2022. PMID: 36211186 Free PMC article. - Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity.
Seals DR, Justice JN, LaRocca TJ. Seals DR, et al. J Physiol. 2016 Apr 15;594(8):2001-24. doi: 10.1113/jphysiol.2014.282665. Epub 2015 Mar 11. J Physiol. 2016. PMID: 25639909 Free PMC article. Review. - Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Boeve BF, Sletten DM, Gehrking TL, Gehrking JA, Olson AD, Savica R, Suarez MD, Soto C, Low PA. Singer W, et al. Ann Neurol. 2020 Sep;88(3):503-512. doi: 10.1002/ana.25824. Epub 2020 Aug 1. Ann Neurol. 2020. PMID: 32557811 Free PMC article. - Time to change the blind men and the elephant approach to Parkinson disease?
Racette BA, Willis AW. Racette BA, et al. Neurology. 2015 Jul 14;85(2):190-6. doi: 10.1212/WNL.0000000000001739. Epub 2015 Jun 12. Neurology. 2015. PMID: 26070339 Free PMC article. Review. - Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations.
Dinov ID, Heavner B, Tang M, Glusman G, Chard K, Darcy M, Madduri R, Pa J, Spino C, Kesselman C, Foster I, Deutsch EW, Price ND, Van Horn JD, Ames J, Clark K, Hood L, Hampstead BM, Dauer W, Toga AW. Dinov ID, et al. PLoS One. 2016 Aug 5;11(8):e0157077. doi: 10.1371/journal.pone.0157077. eCollection 2016. PLoS One. 2016. PMID: 27494614 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical